Newsletter

Life Science Voice Top Five Newsletter January 2023

This week we see that abortion rights continue to be a hot topic in the country with the FDA allowing abortion pills...

Five Things to Know in November 2022

Covering the latest happenings in the pharmaceutical industry - we take a look at a juvenile diabetes drug that took more than...

Five Things to Know in October Third & Fourth Week

Good news for those with hearing difficulties- hearing aids are now available over the counter and at affordable prices! While AstraZeneca gets...

Six Things to Know in October 1st & 2nd Week

A look at the first intestine transplant recipient, Eli Lilly's success in combating obesity, but failure in quality control, and other top...

Six Things to Know in August 2022 Third Week

Moderna sues Pfizer, Zerion develops a dispersome formulation, while Tufts researchers find a way for muscle cells to produce antibodies, along with...

Six Things to Know in August 2022 Second Week

Hope for cancer and HIV patients as new treatments emerge This week we take a look at some crucial...

Six Things to Know in August 2022 1st Week

Monkeypox in pet dog, a hope for diabetes, and other top news this week This week we take a...

Six Things to Know in July 2022

Novavax’s COVID-19 vaccine, OTC birth control pill, and other top news this week Are you interested in the pharma...

Latest news

FDA and CDC exploring unlikely relation between COVID-19 vaccine and stroke

The FDA and CDC have brought out new revelations that the revised COVID-19 injection from Pfizer Inc...

Disappointing sales prompt AstraZeneca to pull out leukemia drug Lumoxiti from U.S. market

In a letter shared with healthcare providers, AstraZeneca has announced that it will be pulling its leukemia...

Sanofi’s Venture Capital units to receive over $750 million in investment to boost firm’s investment capabilities 

After a successful last year in which Sanofi Ventures made its second-highest number of deals, 10 rounds...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

Amgen’s KRAS drug gets early FDA approval for lung cancer with specific mutation

On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC

You might also likeRELATED
Recommended to you

After opioid-meltdown, Mallinckrodt gets ready for company restructuring

Mallinckrodt has closed in on the reorganization...

FDA accelerated approval decision on Alzheimer’s drug likely to come soon

According to Biogen and Eisai, the accelerated...